BioCentury | Mar 27, 2019
Product Development

GW’s next act

...addition, though Epidiolex is GW’s first wholly owned drug, its first approved therapy was Sativex nabiximols...
...outside the U.S. GW thinks Sativex could offer growth opportunities for the company as well. Sativex’s...
...far; GW reported $1.9 million in 4Q18 net product sales. But GW aims to revive Sativex...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...said GW’s big risk was deciding to commercialize Epidiolex itself. GW’s first approved product, Sativex nabiximols...
BioCentury | Mar 24, 2017
Clinical News

AP-CBD/THC: Ph I started

...crossover, Israeli Phase I trial to evaluate 2 formulations of AP-CBD/THC compared to sublingual cannabis extract spray Sativex nabiximols...
BioCentury | Feb 10, 2017
Clinical News

THC:CBD: Ph II data

...recurrent GBM in the double-blind second part of a European Phase II trial showed that THC:CBD...
...83% vs. 53% for placebo plus temozolomide (p=0.042). Median survival was >550 days for the THC:CBD...
...safety of THC:CBD plus temozolomide in 6 patients. GW Pharmaceuticals plc (NASDAQ:GWPH), Salisbury, U.K. Product: THC:CBD...
BioCentury | Feb 7, 2017
Clinical News

GW reports survival data in Phase II GBM study

...GW Pharmaceuticals plc (NASDAQ:GWPH) said data from a Phase II trial showed that THC:CBD (GW42002:GW42003) significantly...
...primary endpoint evaluated safety. Patients received temozolomide plus either THC:CBD or placebo. GW said the THC:CBD...
...of the compound in glioma, but declined to give a timeline for its next steps. THC:CBD...
BioCentury | May 16, 2016
Finance

Global ambitions

...million follow-on in April 2015. GW also benefited from having a marketed product - Sativex nabiximols...
BioCentury | Nov 9, 2015
Clinical News

THC:CBD: Phase I started

...MMJ PhytoTech Ltd. (ASX:MMJ), Nedlands, Australia Product: THC:CBD Business: Autoimmune Molecular target: Cannabinoid receptors Description: Oral...
...and pharmacokinetics Status: Phase I started Milestone: Start Phase II (2016); complete Phase II (2017) MMJ PhytoTech...
...trial to evaluate single doses of 2 formulations of oral THC:CBD in 15 healthy volunteers. MMJ PhytoTech...
BioCentury | Jul 13, 2015
Finance

Big news

...Ph III data 2H15 GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) / Otsuka Pharmaceutical Co. Ltd. Sativex nabiximols...
BioCentury | Jan 12, 2015
Clinical News

Sativex nabiximols: Phase III data

...who experienced inadequate analgesia during optimized chronic opioid therapy showed that 3-10 daily sprays of Sativex...
...period. Data from 2 additional trials of Sativex in the indication are expected this year. Sativex...
...Co. Ltd. , Tokyo, Japan Product: Sativex nabiximols Business: Neurology Molecular target: Cannabinoid receptors Description: Sublingual cannabis extract spray...
BioCentury | Jan 9, 2015
Clinical News

GW's epilepsy timetable eclipses Sativex cancer miss

...Investors ignored a Phase III trial miss for Sativex in cancer pain on Thursday, pushing up...
...In the cancer news, GW and partner Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said Sativex sublingual cannabis extract spray...
...rights in the U.S., where Sativex has Fast Track designation for the cancer pain indication. Sativex...
Items per page:
1 - 10 of 196